Aggrega Pharma is a specialty generic pharmaceutical company focused on developing, manufacturing and marketing niche, complex, high-barrier-to-entry generic medications (injectable, ophthalmic, ER/IR oral, transdermal, spray, and topical finished dosage forms) for the US Market. The shareholders are 4 European companies: Bluepharma (Portugal), Rafarm (Greece), Substipharm (France) and Welding (Germany). Aggrega Pharma is committed to building a selective, valuable pipeline of generic products by leveraging the vast R&D, clinical and manufacturing experience and capabilities of its members. We are continually looking to expand and increase our finished dose portfolio through collaborative working as our partnership offerings combines flexible business models with coordinated process development to strengthen your products, while reducing your risk. Our partnership offering is supported by our in-house development and commercial manufacturing facilities at Bluepharma in Portugal and Rafarm in Greece to meet your global product requirements.